City of Hope

City of Hope, a NCI-designated Comprehensive Cancer Center

Page Title

Skip Navigation

Global Navigation



Border Border
  
Click here to login to Secure Web Site   (authorized users only)  
  
Search results:  58  Clinical trial(s) found  (Page 1 of 3 )
Results per page: 25 50 100 All 1-25 Trials Jump to page:

The following studies are available for :
COH Protocol Number: 14308 ClinicalTrials.gov Number: NCT02257567

Principal Investigator: Alex Herrera, MD
Sponsor: Industrial

Title:  A Phase IB/II Study Evaluating the Safety, Tolerability and Anti-Tumor Activity of Polatuzumab Vedotin (DCDS54501A)in Combination with Rituzimab (R) or Obinutuzumab (G) Plus Bendamustine (B) in Relpased or Refractory Follicular or Diffuse Large B-Cell Lymphoma

COH Protocol Number: 14301 ClinicalTrials.gov Number: NCT02270463

Principal Investigator: Anthony Stein, MD
Sponsor: Industrial

Title:  A Phase 1/2 Study of SL-401 as Consolidation Therapy for Adult Patients with Adverse Risk Acute Myeloid Leukemia in First CR, and/or Evidence of Minimal Residual Disease (MRD) in First CR

COH Protocol Number: 14299 ClinicalTrials.gov Number: NCT02301104

Principal Investigator: Marwan Fakih, MD
Sponsor: Industrial

Title:  A Phase 1, Open-Label Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of TAS-102 in Patients with Advanced Solid Tumors and Varying Degrees of Hepatic Impairment

COH Protocol Number: 14297 ClinicalTrials.gov Number: NCT02206334

Principal Investigator: Savita Dandapani, MD
Sponsor: Cooperative Group

Title:  NRG Oncology NRG-BR001: A Phase 1 Study of Stereotactic Body Radiotherapy (SBRT) for the Treatment of Multiple Metastases

COH Protocol Number: 14285 ClinicalTrials.gov Number: NCT02301117

Principal Investigator: Marwan Fakih, MD
Sponsor: Industrial

Title:  A Phase 1, Open-Label Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of TAS-102 in Patients with Advanced Solid Tumors and Varying Degrees of Renal Impairment

COH Protocol Number: 14265 ClinicalTrials.gov Number: NCT01625234

Principal Investigator: Karen Reckamp, MD
Sponsor: Industrial

Title:  Phase 1/2, First-in-Human, Dose-Escalation Study of X-396 in Patients With Advanced Solid Tumors and Expansion Phase in Patients With ALK-positive Non-Small Cell Lung Cancer

COH Protocol Number: 14262 ClinicalTrials.gov Number: NCT01004224

Principal Investigator: Sumanta Pal, MD
Sponsor: Industrial

Title:  A Phase I, Open-Label, Multi-Center, Dose Escalation Study of Oral BGJ398, a Pan FGF-R Kinase Inhibitor, in Adult Patients with Advanced Solid Malignancies

COH Protocol Number: 14240 ClinicalTrials.gov Number: NCT02348216

Principal Investigator: Tanya Siddiqi, MD
Sponsor: Industrial

Title:  A Phase 1-2 Multi-Center Study Evaluating the Safety and Efficacy of KTE-C19 in Subjects with Refractory Aggressive Non-Hodgkin Lymphoma (NHL)

COH Protocol Number: 14231 ClinicalTrials.gov Number: NCT02220842

Principal Investigator: Leslie Popplewell, MD
Sponsor: Industrial

Title:  A Phase 1b Sudy of the Safety and Pharmacology of MPDL3280A Administered with Obinutuzamab in Patients with Relpased/Refractory Follicular Lymphoma and Diffuse Large B-Cell Lymphoma

COH Protocol Number: 14220 ClinicalTrials.gov Number: NCT02203773

Principal Investigator: Vinod Pullarkat, MD
Sponsor: Industrial

Title:  A Phase 1b Study of ABT-199 (GDC-0199) in Combination with Azacitidine or Decitabine in Treatment Naïve Subjects with Acute Myelogenous Leukemia Who Are >/= 65 Years of Age and Who Are Not Eligible for Standard Induction Therapy

COH Protocol Number: 14212 ClinicalTrials.gov Number: NCT01998971

Principal Investigator: Amrita Krishnan, MD
Sponsor: Industrial

Title:  An Open-Label, Multicenter, Phase 1b Study of JNJ-54767414 (HuMaxCD38) (Anti-CD38 Monoclonal Antibody) in Combination with Backbone Regimens for the Treatment of Subjects with Multiple Myeloma

COH Protocol Number: 14179 ClinicalTrials.gov Number: NCT01526928

Principal Investigator: Karen Reckamp, MD
Sponsor: Industrial

Title:  A Phase 1/2, Open-Label, Safety, Pharmacokinetic and Preliminary Efficacy Study of Oral CO-1686 in Patients with Previously Treated Mutant EGFR Non-Small Cell Lung Cancer (NSCLC)

COH Protocol Number: 14171 ClinicalTrials.gov Number: NCT02216890

Principal Investigator: Sumanta Pal, MD
Sponsor: Industrial

Title:  A Phase 1 Trial of SGN-CD70A in Patients with CD70-positive Malignancies

COH Protocol Number: 14167 ClinicalTrials.gov Number: NCT02206763

Principal Investigator: Karen Reckamp, MD
Sponsor: Industrial

Title:  A Phase 1b Study of Erlotinib and Momelotinib for the Treatment of Epidermal Growth Factor Receptor (EGFR) Mutated EGFR Tyrosine Kinase Inhibitor (TKI) Naïve Metastatic Non-Small Cell Lung Cancer (NSCLC)

COH Protocol Number: 14166 ClinicalTrials.gov Number: NCT01786135

Principal Investigator: Robert Chen, MD
Sponsor: Industrial

Title:  A Phase 1, Open-Label, Dose-Escalation Study of SGN-CD19A in Patients with Relapsed or Refractory B-lineage Non-Hodgkins Lymphoma

COH Protocol Number: 14161 ClinicalTrials.gov Number: NCT02250157

Principal Investigator: Marwan Fakih, MD
Sponsor: Industrial

Title:  A Dose-regimen Finding Study to Evaluate Safety, Tolerability, Pharmacokinetics and Activity of Oratecan in Subjects with Advanced Malignancies

COH Protocol Number: 14160 ClinicalTrials.gov Number: NCT01962792

Principal Investigator: Chatchada Karanes, MD
Sponsor: Industrial

Title:  A Multicenter Phase 1/2b Study of the Bruton’s Tyrosine Kinase Inhibitor, Ibrutinib (PCI-32765), in Combination with Carfilzomib (Kyprolis™) in Subjects with Relapsed or Relapsed and Refractory Multiple Myeloma

COH Protocol Number: 14158 ClinicalTrials.gov Number: NCT02319369

Principal Investigator: Joseph Rosenthal, MD
Sponsor: Industrial

Title:  A Phase 1 Dose Escalation Study of DS-3032B, an Oral MDM2 Inhibitor, in Subjects with Acute Myelogenous Leukemia (AML), Acute Lymphocytic Leukemia (ALL), Chronic Myleogenous Leukemia (CML) in Blast Phase, or High-Risk Myelodysplastic Syndrome (MDS)

COH Protocol Number: 14157 ClinicalTrials.gov Number: NCT02354417

Principal Investigator: Anna Pawlowska, MD
Sponsor: Industrial

Title:  A Phase I Trial of a Single ProHema CB Product (EX Vivo Modulated Human Cord Blood Cells) Following Myeloablative Conditioning for Pediatric Patients with Hematologic Malignancies

COH Protocol Number: 14156 ClinicalTrials.gov Number: NCT02223598

Principal Investigator: Amrita Krishnan, MD
Sponsor: Industrial

Title:  A Phase 1, Dose-Escalation /Dose-Expansion Study Evaluating the Safety, Pharmacokinetics, and Pharmacodynamic Effects of Orally Administered CB-5083 in Patients with Relapsed/Refractory Multiple Myeloma

COH Protocol Number: 14155 ClinicalTrials.gov Number: NCT02151903

Principal Investigator: Ryotaro Nakamura, MD
Sponsor: Industrial

Title:  An Open-Label Extension Study of De-immunized DI-Leu16-IL2 Immunocytokine administered in Patients with B-cell Non-Hodgkin Lymphoma (NHL)

COH Protocol Number: 14138 ClinicalTrials.gov Number: NCT02006485

Principal Investigator: Tanya Siddiqi, MD
Sponsor: Industrial

Title:  A Multi-Center Phase I/Ib Study Evaluating the Efficacy and Safety of Ublituximab, a Third- Generation Anti-CD20 Monoclonal Antibody, in Combination with TGR-1202, a Novel PI3k Delta Inhibitor; and Ibrutinib in Patients with B-cell Malignancies

COH Protocol Number: 14115 ClinicalTrials.gov Number: NCT02195869

Principal Investigator: Ryotaro Nakamura, MD
Sponsor: Industrial

Title:  A Multicenter, Open-Label, Phase 1b/2 Study of Ibrutinib In Steroid Dependent or Refractory Chronic Graft Versus Host Disease

COH Protocol Number: 14086 ClinicalTrials.gov Number: NCT02164006

Principal Investigator: Robert Chen, MD
Sponsor: Industrial

Title:  A Multi-center Phase I/Ib Study Evaluating the Efficacy and Safety of Brentuximab Vedotin in Combination with TGR-1202, a Novel PI3K Delta Inhibitor, in Patients with Hodgkins Lymphoma (HL)

COH Protocol Number: 14044 ClinicalTrials.gov Number: NCT02014558

Principal Investigator: Margaret O'Donnell, MD
Sponsor: Industrial

Title:  A Phase 1/2 Open-Label, Dose Escalation Study Investigating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ASP2215 in Patients with Relapsed or Refractory Acute Myeloid Leukemia

 
Results per page: 25 50 100 All 1-25 Trials Jump to page:

 
 
  
NCI CCC LogoCity of Hope, An NCI-designated Comprehensive Cancer Center, is an innovative biomedical research, treatment and educational institution dedicated to the prevention and cure of cancer and other life-threatening illness.
Best Of logoCity of Hope has been named one of "America's Best Hospitals" in cancer and gynecology by U.S. News & World Report. Read more here...
NCI CCC LogoThe National Comprehensive Cancer Network (NCCN), a not-for-profit alliance of 21 of the world’s leading cancer centers, is dedicated to improving the quality and effectiveness of care provided to patients with cancer.
Best Of logoWe subscribe to the HONcode of the Healthcare on the Net Foundation.